Signal Genetics Increases IPO Target to up to $12.1M | GenomeWeb

NEW YORK (GenomeWeb) – Signal Genetics raised the target amount from its proposed initial public offering to up to $12.1 million.

In an amended Form S-1 filed with the US Securities and Exchange Commission on Friday, the company said it plans to offer 1.15 million shares of its common stock in its IPO at a range of $10 to $12 per share. At the midrange price of $11 the offering would bring in net proceeds of $10.3 million. If the underwriters exercise their overallotment option in full, that figure would rise to $12.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.